We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

3 Neil Woodford High-Yield Picks: GlaxoSmithKline plc, NEXT plc And Legal & General Group Plc

GlaxoSmithKline plc (LON:GSK), NEXT plc (LON:NXT) and Legal & General Group Plc (LON:LGEN) are Woodford’s heavyweight high-yield picks.

| More on:

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

Top fund manager Neil Woodford is not one for chasing high yields that subsequently prove unsustainable. He was out of banks well before the credit crunch smashed payouts in the sector, and he’s dodged the current round of slashed dividends in the mining industry.

But he does hold some stocks that offer yields well above the market average. His FTSE 100 heavyweights with the highest payouts are GlaxoSmithKline (LSE: GSK), Next (LSE: NXT) and Legal & General (LSE: LGEN).

Should you buy Legal & General Group Plc shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Pharma favourite

Glaxo is set to return to earnings growth in 2016 after a number of difficult years. In its results for 2015, released earlier this month, the company reported a decline in core earnings of 15% (at constant exchange rates). This was actually a little better than guidance, but even more welcome was management’s expectation of double-digit growth in 2016.

The integration of new businesses in Vaccines and Consumer Healthcare, the restructuring of the Global Pharmaceuticals division and the acceleration of new product sales should all drive earnings upwards in coming years. In fact, new product sales are now expected to reach management’s £6bn target up to two years earlier than previously guided (2018, rather than 2020).

The board has reiterated its intention to pay a flat 80p dividend for 2016 and 2017, giving an annual yield of 5.8% at a recent share price of 1,386p. With dividend cover improving as earnings growth kicks in, payouts should then be able to resume a healthy upwards trajectory.

Fashion focus

High street stalwart Next has yet to release results for its financial year ended 30 January, but has provided a trading update. The company said an unseasonably warm November and December would drag full-year sales down to just below the bottom end of previous guidance, but that profit was still on track thanks to good control of margins, costs and stock.

The company has paid out 153p of ordinary dividends during the fiscal year and 230p of special dividends, giving a total running yield of 5.7% at a recent share price of 6,750p. Special dividends (and share buybacks) are an ongoing feature of Next’s focus on delivering value to shareholders. And an increase in payouts is forecast for the year to January 2017, lifting the yield to 6%.

Insurance income

Analysts expect Legal & General to declare a final dividend of 9.9p when it announces its annual results on 15 March. Added to the last interim payout of 3.45p, this gives 13.35p, and a yield of 6.1% at a recent share price of 218p. Expected growth drives the forecast yield for 2016 up to 6.5%.

Something of a changing of the guard is underway at Legal & General, with separate announcements of the retirement of both the chairman and finance director having been made in recent months. Investors have also been a little unnerved by L&G’s potential exposure to bonds in the troubled oil and mining sectors. However, the company detailed its limited exposure to these sectors earlier this month.

Woodford and his team remain “very positive on the prospect of consistent and attractive long-term dividend growth”.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female couple boarding their plane at the airport to go on holiday.
Investing Articles

Can the Rolls-Royce share price reach £15.97 by the end of August?

The Rolls-Royce share price has had a solid run in the last year. Muhammad Cheema takes a look at whether…

Read more »

Santa Clara offices of NVIDIA
Investing Articles

Up 1,200% in 5 years, here’s why Nvidia could still be a brilliant value stock

An exciting new announcement that could reshape the PC industry has just pushed Nvidia stock... well, just about nowhere really.

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

How investing £4.50 a day could set you on the way to a £1,505 monthly second income

How can UK stocks with high dividend yields help investors earn a meaningful second income from the price of a…

Read more »

Investing Articles

Up 103% with a P/E of 261 — is this FTSE 100 stock still worth buying?

One FTSE 100 stock is quietly moving higher while most investors are still looking elsewhere — is the market missing…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

The smart money thinks AI stocks look risky — but is there still a chance to buy?

According to fund managers, the AI trade is getting crowded. But they still seem to think it’s the place to…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Barclays shares are 11% below their 52-week high. Could they be a bit of a bargain to consider?

Overpriced or one of the FTSE 100’s hidden gems? James Beard takes a closer look at how the market is…

Read more »

Stack of one pound coins falling over
Investing Articles

Down 65% but yielding 6.7% – is this beaten-down UK stock now a generational bargain?

Harvey Jones says this UK stock is one of the worst FTSE 100 performers but there are sound reasons to…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

Is this FTSE stock really 46% undervalued?

Analysts reckon this FTSE stock should be worth nearly 50% more. James Beard considers why there’s so much positivity surrounding…

Read more »